Metastatic Prostate Cancer: Background and Patient Prognosis

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

Now Viewing

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.